Advanced recurrent ovarian cancer medication and treatment.docVIP

 PAGE \* MERGEFORMAT 8 Advanced recurrent ovarian cancer medication and treatment Advanced, recurrent ovarian cancer often require chemotherapy and surgery again, this second-line chemotherapy and cytoreductive surgery again and efficacy of the medication described below. A second-line chemotherapy for ovarian cancer Cisplatin-based combination chemotherapy used in treatment of ovarian cancer, and get better results, but after initial chemotherapy, 40% to 60% of patients relapse, with the initial chemotherapy ineffective for some patients, this means that the majority of ovarian cancer patients need chemotherapy again, that the second chemotherapy according to initial chemotherapy, patients can be divided into drug-resistant, resistant and sensitive of three. is generally believed that chemotherapy resistance is the primary objective can not produce those effects, drug resistance after chemotherapy is a certain effect, but remission is short, relapse within six months, is sensitive to produce objective response after chemotherapy, tumor-free remission for over six months were. against drug-resistant should be used or second-line chemotherapy today have some effect on ovarian cancer second-line chemotherapy are: 1.1 Taxol (paclitaxel) produced by the DDP resistant or treatment-resistant should be the preferred second-line paclitaxel chemotherapy dose of 135mg · m-2, 24h infusion every 3 weeks and its main toxicity occurred 3 to 4 neutropenia, the rate was 78%, and therefore the treatment needs of granulocyte colony stimulating factor GCSF. higher doses of paclitaxel increased adverse reactions, in addition to bone marrow suppression, there are anemia, gastrointestinal toxicity, neurotoxicity, etc. According to recent reports [1], with paclitaxel 165mg · m-2, 3h infusion, treatment of DDP-resistant, the effective rate of 51.3%, median survival period of 10 months is recommended 175mg · m-2, 3h infusion treatment of relapsed cases. 1.2 Topo